Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Sangamo Therapeutics Inc (NASDAQ: SGMO) was $0.45 for the day, down -1.98% from the previous closing price of $0.46. In other words, the price has decreased by -$1.98 from its previous closing price. On the day, 4.42 million shares were traded. SGMO stock price reached its highest trading level at $0.4682 during the session, while it also had its lowest trading level at $0.4497.
Ratios:
Our analysis of SGMO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.88 and its Current Ratio is at 0.88. In the meantime, Its Debt-to-Equity ratio is 4.07 whereas as Long-Term Debt/Eq ratio is at 4.07.
On December 13, 2024, Truist Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $7.
H.C. Wainwright reiterated its Buy rating for the stock on December 10, 2024, and also maintained the target price at $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 151422512 and an Enterprise Value of 147230528. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.61 while its Price-to-Book (P/B) ratio in mrq is 23.21. Its current Enterprise Value per Revenue stands at 4.478 whereas that against EBITDA is -1.406.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.29, which has changed by -0.82641506 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $2.84, while it has fallen to a 52-week low of $0.38. The 50-Day Moving Average of the stock is -17.70%, while the 200-Day Moving Average is calculated to be -24.97%.
Shares Statistics:
SGMO traded an average of 6.47M shares per day over the past three months and 7174360 shares per day over the past ten days. A total of 336.49M shares are outstanding, with a floating share count of 329.09M. Insiders hold about 2.45% of the company’s shares, while institutions hold 18.72% stake in the company. Shares short for SGMO as of 1764288000 were 17420411 with a Short Ratio of 2.69, compared to 1761868800 on 14190116. Therefore, it implies a Short% of Shares Outstanding of 17420411 and a Short% of Float of 5.2199997.
Earnings Estimates
As of right now, 2.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.4 and -$0.42 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.23, with 2.0 analysts recommending between -$0.12 and -$0.34.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $100M to a low estimate of $10M. As of. The current estimate, Sangamo Therapeutics Inc’s year-ago sales were $7.55MFor the next quarter, 4 analysts are estimating revenue of $20.55M. There is a high estimate of $24.8M for the next quarter, whereas the lowest estimate is $16.3M.
A total of 4 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $125.3M, while the lowest revenue estimate was $35.3M, resulting in an average revenue estimate of $65.55M. In the same quarter a year ago, actual revenue was $57.8MBased on 4 analysts’ estimates, the company’s revenue will be $55.38M in the next fiscal year. The high estimate is $114.2M and the low estimate is $8.6M.
